Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Whole-body deletion of Endospanin 1 protects from obesity-associated deleterious metabolic alterations
Arturo Roca-Rivada, Marcio Do Cruzeiro, Raphaël G.P. Denis, Qiang Zhang, Christine Rouault, Yves Rouillé, Jean-Marie Launay, Céline Cruciani-Guglielmacci, Virginie Mattot, Karine Clément, Ralf Jockers, Julie Dam
Arturo Roca-Rivada, Marcio Do Cruzeiro, Raphaël G.P. Denis, Qiang Zhang, Christine Rouault, Yves Rouillé, Jean-Marie Launay, Céline Cruciani-Guglielmacci, Virginie Mattot, Karine Clément, Ralf Jockers, Julie Dam
View: Text | PDF
Research Article Cell biology Metabolism

Whole-body deletion of Endospanin 1 protects from obesity-associated deleterious metabolic alterations

  • Text
  • PDF
Abstract

The importance of the proper localization of most receptors at the cell surface is often underestimated, although this feature is essential for optimal receptor response. Endospanin 1 (Endo1) (also known as OBRGRP or LEPROT) is a protein generated from the same gene as the human leptin receptor and regulates the trafficking of proteins to the surface, including the leptin receptor. The systemic role of Endo1 on whole-body metabolism has not been studied so far. Here, we report that general Endo1-KO mice fed a high-fat diet develop metabolically healthy obesity with lipid repartitioning in organs and preferential accumulation of fat in adipose tissue, limited systematic inflammation, and better controlled glucose homeostasis. Mechanistically, Endo1 interacts with the lipid translocase CD36, thus regulating its surface abundance and lipid uptake in adipocytes. In humans, the level of Endo1 transcripts is increased in the adipose tissue of patients with obesity, but low levels rather correlate with a profile of metabolically healthy obesity. We suggest here that Endo1, most likely by controlling CD36 cell surface abundance and lipid uptake in adipocytes, dissociates obesity from diabetes and that its absence participates in metabolically healthy obesity.

Authors

Arturo Roca-Rivada, Marcio Do Cruzeiro, Raphaël G.P. Denis, Qiang Zhang, Christine Rouault, Yves Rouillé, Jean-Marie Launay, Céline Cruciani-Guglielmacci, Virginie Mattot, Karine Clément, Ralf Jockers, Julie Dam

×

Figure 6

Low levels of Endo1 correlate with improved glucose homeostasis in obese humans.

Options: View larger image (or click on image) Download as PowerPoint
Low levels of Endo1 correlate with improved glucose homeostasis in obese...
(A) LEPROT transcript levels in humans with obesity versus lean humans. Results are expressed as mean ± SEM (n ≥ 5). *P < 0.05 versus humans with obesity. Two-tailed t test. (B) LEPROT mRNA levels in patients with obesity and with impaired glucose tolerance (GI) or type 2 diabetes (T2D) compared with normoglycemic patients with obesity (18 years < age < 55 years; 36 < BMI < 49). Results are expressed as mean ± SEM (n ≥ 6). Two-tailed t test. (C) Contingency distribution of lean individuals and patients with obesity according to low, medium, or high LEPROT mRNA levels classified by tertiles. A χ2 test was used. (D) Contingency distribution of patients with obesity according to low, intermediate, or high LEPROT levels and grouped into 3 HOMA-IR index categories. The χ2 test between low and high LEPROT gives a P value of 0.052.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts